Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q10570

UPID:
CPSF1_HUMAN

ALTERNATIVE NAMES:
Cleavage and polyadenylation specificity factor 160 kDa subunit

ALTERNATIVE UPACC:
Q10570; Q96AF0

BACKGROUND:
Cleavage and polyadenylation specificity factor subunit 1, alternatively named the 160 kDa subunit, is integral to mRNA processing, specifically in 3'-end formation. It is involved in recognizing the AAUAAA sequence, facilitating cleavage and poly(A) addition, essential for mRNA stability and translation. Its role extends to eye development and the formation of retinal ganglion cell projections.

THERAPEUTIC SIGNIFICANCE:
This protein's mutation is associated with Myopia 27, an autosomal dominant disorder leading to early-onset high myopia. The condition features significant axial lengthening and distinct optic nerve and retinal changes. Exploring the functions of Cleavage and polyadenylation specificity factor subunit 1 offers a promising avenue for developing treatments for myopia and its complications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.